Investigators at University of British Columbia have reported the precise cellular populations responsible for the inability to regenerate muscle tissues in muscular dystrophy.

Investigators at the Weizmann Institute of Science have identified changes in oligodendrocytes that were shared across multiple dementia types. The team reported its results in the June 27, 2022, online issue of Nature Neuroscience.

Connections, Susan Greenfield told her audience at the 2022 Annual Conference of the European Academy of Neurology, are what the mind is all about. "When you are born, you are born with a fair amount of neurons," she said at the conference's opening plenary on Sunday. But "what characterizes the growth of the brain postnatally is the configurations of connections."

Research led by the University of Texas Southwestern Medical Center reveals a protein signature that can reliably predict whether patients with nonalcoholic fatty liver disease (NAFLD) are likely to develop hepatocellular carcinoma, the most common form of liver cancer.

A possible route to depleting leukemic stem cells while preserving healthy hematopoietic stem cells has opened up, with the discovery that cyclin-dependent kinase regulatory subunit 1 inhibition suppresses cancer stem cells and at the same time protects healthy stem cells from the toxic effects of chemotherapy.

Investigators at Stanford University and Baylor College of Medicine have identified an exercise-induced appetite suppressant that led to weight loss when administered to obese mice. The molecule, Lac-Phe, has led to predictable excitement around the possibility of appetite-suppressing exercise in a pill.

Failure to ovulate and release mature oocytes is one of the most common female infertility problems. With increasing age or conditions like obesity, no oocytes are released even on ovulation induction with hormonal treatment.

Researchers at Hannover Medical School have gained new insights into the cytokine meteorin-like (METRNL) and its role in promoting heart repair after myocardial infarction.

It is well known that the development of a new drug is exorbitantly expensive and is a process which usually fails. Researchers at PrecisionLife posit that failure and the many patients with unmet treatment needs result from an over simplistic view of disease pathogeneses and an overreliance on a narrow range of target genes and pathways.

The eyes may be the window to the heart as well as the soul – particularly, to whether that heart is at risk of an infarct, researchers reported last week at the annual congress of the European Society of Human Genetics.